Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMD NASDAQ:BYSI NASDAQ:NLTX NASDAQ:SPPI NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.25$0.07▼$5.48$2.92M2.074.87 million shs22.99 million shsBYSIBeyondSpring$1.79-6.8%$1.92$0.98▼$3.44$77.44M0.2227,728 shs76,707 shsNLTXNeoleukin Therapeutics$17.20-7.9%$20.44$2.03▼$14.36$161.65M1.1150,104 shs215,471 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVKTXViking Therapeutics$26.25+3.3%$30.35$18.92▼$81.73$2.86B0.735.42 million shs7.86 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%-95.08%BYSIBeyondSpring-6.77%-4.28%+1.70%-26.94%-15.96%NLTXNeoleukin Therapeutics0.00%-9.47%-13.96%-0.12%-57.79%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics+3.35%+9.01%+0.96%-2.60%-62.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.25$0.07▼$5.48$2.92M2.074.87 million shs22.99 million shsBYSIBeyondSpring$1.79-6.8%$1.92$0.98▼$3.44$77.44M0.2227,728 shs76,707 shsNLTXNeoleukin Therapeutics$17.20-7.9%$20.44$2.03▼$14.36$161.65M1.1150,104 shs215,471 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVKTXViking Therapeutics$26.25+3.3%$30.35$18.92▼$81.73$2.86B0.735.42 million shs7.86 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%-95.08%BYSIBeyondSpring-6.77%-4.28%+1.70%-26.94%-15.96%NLTXNeoleukin Therapeutics0.00%-9.47%-13.96%-0.12%-57.79%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics+3.35%+9.01%+0.96%-2.60%-62.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 2.00Hold$3.621,895.87% UpsideBYSIBeyondSpring 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/ASPPISpectrum Pharmaceuticals 0.00N/AN/AN/AVKTXViking Therapeutics 3.00Buy$90.38244.32% UpsideCurrent Analyst Ratings BreakdownLatest AFMD, VKTX, BYSI, NLTX, and SPPI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/22/2025VKTXViking TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.008/19/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.007/24/2025VKTXViking TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$125.00 ➝ $122.007/24/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $38.006/25/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K3.33N/AN/A$4.19 per share0.04BYSIBeyondSpring$1.75M41.25N/AN/A($0.37) per share-4.84NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ASPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%N/ABYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/A11/12/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ASPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AVKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest AFMD, VKTX, BYSI, NLTX, and SPPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BYSIBeyondSpringN/A-$0.04N/A-$0.04N/AN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93BYSIBeyondSpringN/A2.192.19NLTXNeoleukin TherapeuticsN/A15.3315.33SPPISpectrum PharmaceuticalsN/A2.712.38VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%BYSIBeyondSpring40.29%NLTXNeoleukin Therapeutics52.37%SPPISpectrum Pharmaceuticals21.67%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%BYSIBeyondSpring29.31%NLTXNeoleukin Therapeutics1.58%SPPISpectrum Pharmaceuticals2.70%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionOptionableBYSIBeyondSpring8040.33 million28.51 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableVKTXViking Therapeutics20112.44 million107.84 millionOptionableAFMD, VKTX, BYSI, NLTX, and SPPI HeadlinesRecent News About These CompaniesExchange Traded Concepts LLC Buys 20,296 Shares of Viking Therapeutics, Inc. $VKTX5 hours ago | marketbeat.comViking Therapeutics: Oral Study Disappoints, Competitor Gets Bought Out (Rating Downgrade)September 23 at 2:56 AM | seekingalpha.comViking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call TranscriptSeptember 22 at 2:05 PM | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from BTIG ResearchSeptember 22 at 11:07 AM | marketbeat.comKingstone Capital Partners Texas LLC Makes New $1.37 Million Investment in Viking Therapeutics, Inc. $VKTXSeptember 22 at 3:59 AM | marketbeat.comStrs Ohio Takes Position in Viking Therapeutics, Inc. $VKTXSeptember 21 at 3:02 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 10.6% - Should You Buy?September 19, 2025 | marketbeat.comPrediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 MonthsSeptember 19, 2025 | fool.comViking Therapeutics, Inc. $VKTX Shares Sold by Harbor Capital Advisors Inc.September 18, 2025 | marketbeat.comViking Therapeutics, Inc. (VKTX): A Bull Case TheorySeptember 18, 2025 | finance.yahoo.comBiotech Breakouts: 3 Stocks With Massive Upside Potential (VKTX)...September 17, 2025 | marketbeat.comWesbanco Bank Inc. Has $1.38 Million Holdings in Viking Therapeutics, Inc. $VKTXSeptember 17, 2025 | marketbeat.comViking Therapeutics, Inc. $VKTX Position Reduced by Voya Investment Management LLCSeptember 17, 2025 | marketbeat.comViking Therapeutics, Inc. (VKTX): A Bull Case Theory September 16, 2025 | insidermonkey.comAMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?September 16, 2025 | zacks.comViking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to KnowSeptember 15, 2025 | zacks.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Buy" by BrokeragesSeptember 15, 2025 | marketbeat.comWoodline Partners LP Acquires 207,784 Shares of Viking Therapeutics, Inc. $VKTXSeptember 14, 2025 | marketbeat.comWealth Management Associates Inc. Purchases Shares of 9,975 Viking Therapeutics, Inc. $VKTXSeptember 13, 2025 | marketbeat.comAlliancebernstein L.P. Decreases Position in Viking Therapeutics, Inc. $VKTXSeptember 12, 2025 | marketbeat.comViking Therapeutics (VKTX): Reassessing Valuation After Clinical Trial Setback and Weak EarningsSeptember 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025AFMD, VKTX, BYSI, NLTX, and SPPI Company DescriptionsAffimed NASDAQ:AFMDAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.BeyondSpring NASDAQ:BYSI$1.79 -0.13 (-6.77%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$1.85 +0.06 (+3.35%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Neoleukin Therapeutics NASDAQ:NLTX$17.20 -1.48 (-7.92%) As of 09/19/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Viking Therapeutics NASDAQ:VKTX$26.25 +0.85 (+3.35%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$26.46 +0.20 (+0.78%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Why Robinhood Stock Is Soaring—and What Comes Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
